دورية أكاديمية
Combined protection of vaccination and nirmatrelvir-ritonavir against hospitalization in adults with COVID-19.
| العنوان: | Combined protection of vaccination and nirmatrelvir-ritonavir against hospitalization in adults with COVID-19. |
|---|---|
| المؤلفون: | Shah MM; Coronavirus and Other Respiratory Viruses Division, National Center for Immunization and Respiratory Diseases, CDC., Joyce B; Epic Research, Epic Systems Corporation, Verona, Wisconsin, USA., Plumb ID; Coronavirus and Other Respiratory Viruses Division, National Center for Immunization and Respiratory Diseases, CDC., Sahakian S; Epic Research, Epic Systems Corporation, Verona, Wisconsin, USA., Feldstein LR; Coronavirus and Other Respiratory Viruses Division, National Center for Immunization and Respiratory Diseases, CDC., Barkley E; Epic Research, Epic Systems Corporation, Verona, Wisconsin, USA., Paccione M; Epic Research, Epic Systems Corporation, Verona, Wisconsin, USA., Deckert J; Epic Research, Epic Systems Corporation, Verona, Wisconsin, USA., Sandmann D; Epic Research, Epic Systems Corporation, Verona, Wisconsin, USA., Hagen MB; Coronavirus and Other Respiratory Viruses Division, National Center for Immunization and Respiratory Diseases, CDC., Gerhart JL; Epic Research, Epic Systems Corporation, Verona, Wisconsin, USA. |
| المصدر: | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America [Clin Infect Dis] 2024 Feb 27. Date of Electronic Publication: 2024 Feb 27. |
| Publication Model: | Ahead of Print |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Oxford University Press Country of Publication: United States NLM ID: 9203213 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1537-6591 (Electronic) Linking ISSN: 10584838 NLM ISO Abbreviation: Clin Infect Dis Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: Jan. 2011- : Oxford : Oxford University Press Original Publication: Chicago, IL : The University of Chicago Press, c1992- |
| مستخلص: | Among U.S. adults at risk for severe COVID-19 in Epic Cosmos, the lowest rate of hospitalization was among those receiving three or more mRNA vaccine doses and nirmatrelvir-ritonavir (aHR 0.22, 95%CI: 0.19-0.24). Adults who are at high-risk of severe COVID-19 disease, including vaccinated persons, should be considered for antiviral treatment. (© Published by Oxford University Press on behalf of Infectious Diseases Society of America 2024.) |
| فهرسة مساهمة: | Keywords: SARS-CoV-2; covid-19; nirmatrelvir-ritonavir; vaccination |
| تواريخ الأحداث: | Date Created: 20240227 Latest Revision: 20240227 |
| رمز التحديث: | 20240227 |
| DOI: | 10.1093/cid/ciae105 |
| PMID: | 38411622 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1537-6591 |
|---|---|
| DOI: | 10.1093/cid/ciae105 |